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Im m unohistochem ical expression of SKALP/elafin in 
squam ous cell carcinom a of the oesophagus
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Summary In this study, the immunohistochemical expression of a new inducible elastase inhibitor, SKALP (skin-derived anti- 
leucoproteinase)/elafin, in the tissue of squamous cell carcinoma and uninvolved oesophageal mucosa was studied using a polyclonal rabbit 
anti-serum against SKALP/elafin. The results were compared with the immunohistochemical staining of proliferating cell nuclear antigen 
(PCNA) and the TUNEL assay in serial sections. In non-malignant oesophageal mucosa, the expression of SKALP/elafin was localized in the 
cells of the stratified zone overlying the PCNA-positive basal zone. In oesophageal cancer, the incidence of the expression was significantly 
related to the degree of the differentiation of the tumour. Characteristically, the expression was almost limited in tumour cell nests that had a 
clear squamous phenotype. In tumour cell nests, the expression of SKALP/elafin was localized in the cells overlying PCNA-expressing cells 
and no expression was found in the cells that expressed PCNA; DNA fragmentation was often observed in the same cell layers as those in 
which SKALP/elafin immunoreactivity was found. This enzyme inhibitor is speculated to be involved in the induction of the cell differentiation 
and apoptosis of human squamous cell carcinoma cells of the oesophagus.
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Squamous cell carcinoma (SCC) is the major histological type o f
being one o f  the most lethal 
neoplasms o f  the digestive organs. At present, only limited 
numbers of patients can be cured by conventional therapy, such as 
surgical resection, irradiation and chemotherapy, one reason being 
that oesophageal cancer has an extremely high potential for 
invasion into the surrounding organs and for metastasis. Several 
proteases produced by the cancer cell itself have been reported to 
be associated with cancer invasion and metastasis (Liotta el al,
1980, 1986, 19 9 1; Wooley, 1984; Nakajima et al, 1987; Reich 
el al, 1988; Basset et al, 1990). Also several kinds o f specific 
inhibitors o f  such proteases have been shown to inhibit cancer 
invasion and metastasis (Baker et al, 1990; Cajol et al, 1990; 
Albini et al, 19 9 1; Deelerck et al, 1992; Kennedy, 1994;
1990, 1993). Differential expression has also been observed in a 
number o f  epidermal tumours (Alkemade el al, 1993). However, 
no information is available concerning the squamous cell carci­
noma of the oesophagus.
In this study, lo elucidate Ihe biological significance of this 
enzyme inhibitor, the immimohistochemieal expression of
SKALP/elafin in the tissues o f  squamous cell carcinoma and unin­
volved oesophageal mucosa was examined using a polyclonal rabbit 
anti-serum against SKALP/elafin. In addition, the evaluation of the 
relationship between the immunohistochemical staining o f prolifer­
ating cell nuclear antigen (PCNA) and the TDT-medialed dlJTP- 
digoxigenin nick end labelling (TUNEL assay) and the expression 
of this enzyme inhibitor was performed using serial sections, This is 
ihe first report lo analyse the expression of SKALP/elafin in
Kobayashi el al, 1994, 1995). Hence, the protease inhibitors could squamous cell carcinoma of ihe human oesophagus, 
be considered to possess the potential to be a useful tool for the 
development o f  a new therapeutic method against cancer.
Recently, a new inducible elastase inhibitor, SKALP (skin- 
derived antilcucoproteinase) has been isolated from psoriatic skin Isolation and purification of SKALP/elafin
MATERIALS AND METHODS
(Schalkwijk el al, 1990, 1993). SKALP has been shown lo be a 
heat-stable, cationic protein with an apparent molecular weight of  
9-11 kDa. DNA of SKALP has been cloned and sequenced 
(Schalkwijk et al, 1991) and has proved lo be identical to elafin, 
which is a similar epidermal protease inhibitor described by 
Wiedow el al (1990). The expression o f  SKALP/elafin has nol 
been found in the cells o f  normal epidermis but is found in differ­
entiating cells o f  psoriasis and wound healing (Schalkwijk et al,
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The method of the isolation and purification of SKALP/elafin bolh 
from psoriatic scales and from cultured human keralinoeyles has 
been described previously (Schalkwijk et al, I990, 1991). In brief, 
psoriatic scales were homogenized in distilled water, yielding a 
suspension that was boiled and centrifuged, followed by chloro­
form extraction and centrifugalion. After concentration, the 
preparation was further purified by chromatofocusing (PBE 118 
column, triethylamine buffer) and affinity chromatography 
[porcine pancreatic elastase coupled to cyanogen 
activated Sepharose 4B, phosphate-buffered saline (PBS) washing 
buffer and 0 . 1 m acetic acid eluting bul'fer|, Final purification was 
by gel permeation chromatography on a Superdex-75 fast protein 
liquid chromatography column. Extracts o f  cultured keralinoeyles
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were prepared by sonication o f the cells in distilled water and were Immunohistochemistry
subjected to the Smart chromatography system (Superdex 75 PC 
2.3/30 column). Anti-elastase activity in obtained fractions was 
measured; relevant fractions were pooled and vacuum evaporated 
to dryness.
Here, the avitin-biotin-peroxidase complex (ABC) method was 
performed using the Vectastatin ABC Kit (Vector Laboratories, 
Burlingame, CA, USA). Briefly, sections were depuraffinized in 
xylene and rehydrated in a graded solution of ethanol. After
Anti-SKALP/elafin serum
quenching the endogenous peroxidase activity in absolute 
methanol containing 0.3% (w/v) hydrogen peroxide for 30 min.
The method of the production o f  a polyclonal rabbit anti- 
SKALP/elafin serum has been reported previously (Schalkwijk et 
al, 1991 ; Alkemade et al, 1993). In brief, a rabbit was immunized 
intracutaneously with highly purified SKALP/elafin that was
cross-linked with glutaraldehyde and emulsified in 
Freund’s complete adjuvant. A booster with the same preparation 
was given after 2 weeks, and 4  weeks later serum was collected via 
standard methods. The specificity o f  the antiserum was validated 
in functional assays and on Western blots, which showed that 
(1) the immunohistochemical reactivity o f  antiserum could be 
absorbed by SKALP/elafin and the elastase-inhibiting activity 
could be absorbed by sepharose 4B-conjugated immunoglobulins 
purified from anti-SKALP/elafin serum by protein A chromatog­
raphy; and that (2) the band stained on a Western blot corre­
sponded with a band o f  anti-elastase activity eluted from the 
SDS-PAGE gel as shown previously (Schalkwijk et al, 1991; 
Alkemade et al., 1993).
non-specific binding was blocked by treatment with 1.5% (w/v) 
normal horse serum (Vector) for 30 min. A polyclonal rabbit anti- 
SKALP/elafin serum was applied to the sections at a dilution o f  
1:500, and each specimen was incubated in a moist chamber for 
2 h at room temperature. After the sections were washed three times 
in 0.05 mol 1' phosphate-buffered saline (PBS, pH 7.2), biotinyl- 
ated anti-rabbit IgG (Vector) was applied at a dilution o f  1:200. 
The sections were again incubated for 50 min at room temperature. 
Freshly prepared ABC reagent (Vector) was applied and incubated 
for 60 min after three washes in PBS. The localization o f  
SKALP/elafin was visualized by incubating the sections for 5 min 
in freshly prepared 0.05 mol 1' Tris-HCl (pH 7.6) containing both 
0.02% (w/v) 3,3-diaminobenzidine tetrahydrochloride (Nakalai 
Tesque, Kyoto, Japan) (D A B  solution) and 0.03% (w/v) hydrogen 
peroxidase. The control slides were prepared as follows: (1) 
sections were processed without primary antibody; and (2) normal 
rabbit serum and non-specific rabbit IgG were used instead o f  a 
polyclonal anti-SKALP/elafin serum.
Tissues
A total of 34  tissues o f oesophageal carcinoma as well as Immunohistochemical PCNA staining
uninvolved oesophageal mucosa were obtained from surgical 
specimens resected at the Department o f  Surgery II, Kumamoto 
University Hospital, between 1989 and 1994 without any preoper­
ative treatment. The patients consisted o f  30 men and four women. 
Their average age was 64.1 years.
All specimens were immediately fixed in 10% (v/v) buffered 
formalin and embedded in paraffin. Four-micron-thick sections 
were prepared from each sample and processed for immunohisto­
chemistry with anti-SKALP/elafin serum and MAb anti-PCNA  
antibody, using TUNEL assay and, for routine examination, 
haematoxylin and eosin (HE)-stained sections.
Immunohistochemical PC N A  staining was performed using the 
Vectastatin ABC Kit (Vector). The sections were treated with 3% 
hydrogen peroxidase for 30 min to block endogenous peroxidase 
activity and were incubated with 1.5% (w/v) normal horse serum 
to block non-specific binding o f  the antibody. They were incu­
bated with mouse monoclonal anti-PCNA antibody (CLA 16/1) 
(Medac, Hamburg, Germany), diluted 1:200 overnight at4°C , then 
incubated with biotinylated rabbit anti-mouse IgG (Vector) for 
30 min. Freshly prepared A B C  Reagent (Vector) was applied and 
incubated for 60 min. Finally, they were incubated with DAB solu­
tion containing 0.03% (w/v) hydrogen peroxidase. Between each
step, the sections were washed in PBS for 5 min three times and
Clinicopathological factors
The immunohistochemical findings were correlated with histolog­
ical type, depth of invasion (T), lymphatic involvement (N), distant 
metastasis (M) and clinical stage. These were basically in accord 
with the TNM classification (1987) (The Japanese Society for 
Esophageal Diseases, 1992). The histological types o f  SCC can 
vary within the same tumour. Usually, one tumour contains multiple
then counterstained in M ayer’s haematoxylin. The control slides
were as follows: sections were without
primary antibody, and non-specific mouse IgG was used instead o f  
primary antibody.
TUNEL assay
sites with different differentiation. Therefore, the histological type The TUNEL assay was performed using the Apop Tag In Situ 
o f  the tumour was defined according to the predominant histolog- Apoptosis Detection Kit (Oncor, Gaitherburg, MA, USA). Polit­
ical finding in each case. The 34 oesophageal carcinoma tissues micron-thick tissue sections were incubated with 20 mg ml 1 of  
were morphologically classified into eight well differentiated, 13 proteinase K (Boehringer, Mannheim, Germany) for 15 min at 
moderately differentiated, 11 poorly differentiated squamous cell room temparature. Digestion was stopped by washing in distilled 
carcinomas and two undifferentiated carcinomas. The depth o f  water four times. Sections were then incubated with TdT enzyme 
invasion was classified into four groups: T l ,  tumour invades lamina (Oncor) containing potassium cacodylate as a buffer for 60 min at 
propria or submucosa; T2, tumour invades muscularis propria; T3, 37°C. Specimens were incubated with pre-warmed Stop/Wash 
tumour invades adventitia; T4, tumour invades adjacent structure. Buffer (Oncor) for 30 min at 37°C. After washing in three 
The lymphatic involvement and distant metastasis were classified changes o f  PBS for 5 min, specimens were incubated with anti- 
into two groups, positive and negative. No distant metastases were digoxigenin peroxidase (Oncor) for 30 min at room temperature in
observed in any o f  the tumours in this study. a humidified chamber. The reaction was visualized by adding
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Table 1 Relationship between the expression of SKALP/elafin and the 
clinicopathological factors of the oesophageal carcinomas
Immunoreactivity 
+ - P-value
Histology
Squamous cell carcinoma
Well differentiated 8 0 «
Moderately differentiated 11 2 P=  0.010
Poorly differentiated 6 5
9 f  f w
Undifferentiated carcinoma 0 2 !
Depth of invasion
T1 (m,sm) 6 3 '
12 (mp) 4 3 P=  0.641
T3 (al,a2) 13 3
T4 (a3) 2 0 ,
Lymph node metastasis ■r
N (+) 14 5 F =0.393
N H 9 1 a
Histological stage
1 6 1 1
II 3 01 1 P=  0.310
III 9 3
IV 6 5 .
m, lamia propria; sm, submucosa; mp, muscularls propria; a1, invasion 
reaching adventitia; az, definite invasion to adventitia; a3, invasion into
neighbouring structures.
of SKALP/elafin was found to be localized in the cells o f  the strati­
fied zone adjacent papillae of basal cells or overlying hyperplastic 
basal zone (Figure 1). The expression was not found in the cells o f  
basal zone in any of the specimens. The areas that showed 
SKALP/elafin expression were often found to be accompanied with 
submucosal inflammatory cell infiltration or with mucosal damage 
(Figure 1A). The expression was not observed in normal areas o f  
oesophageal mucosa and in the cells o f  oesophageal glands (Figure 
IB). The cytoplasmic granular pattern was most pronounced with 
staining. The control slides were negative in all tissue samples 
studied.
The expression of PCNA was observed in the cells o f  
oesophageal mucosa, accompanying the hyperplastic changes. In 
most cases, the expression of SKALP/elafin and PCNA was 
observed in the same area as non-malignant oesophageal mucosa. 
However, the staining cell layers were clearly separated. PCNA  
was expressed in the nucleus o f the cells in papillae or in the 
hyperplastic basal zone. In contrast, SKALP/elafin was expressed 
in the cells of the stratified zone adjacent to PCNA-expressing  
basal cells (Figure 2). No expression o f SKALP/elafin was found 
in the cells that expressed PCNA.
Oesophageal cancer
Of 34 oesophageal carcinomas examined, 25 (73.5%) showed
immunoreactivity with anti-SKALP/elafin serum. The staining 
pattern varied from diffuse cytoplasmic to cytoplasmic granular. 
Strong expression was observed in tumour cell nests that had a 
clear squamous phenotype (Fig. 3A). Staining cells were localized  
in the cell layer just underneath the cornified cell layer of tumour 
cell nests. As seen in non-malignant oesophageal mucosa, no 
expression was observed in the cells o f  the basal layer in tumour
Figure 4 Immunohistochemical staining for SKALP/elafin in poorly 
differentiated squamous cell carcinoma of the oesophagus. Positive staining 
was localized in tumour cell nests with a clear squamous phenotype. 
Magnification x40
cell nests. The wall o f  the cornified cells in tumour cell nests was 
also found to be positive.
The relationship between the expression o f SKALP/elafin and 
the clinicopathological factors of oesophageal cancer is shown in 
Table 1. The expression o f SKALP/elafin was significantly related
to the differentiation of the tumour. The of
SKALP/elafin was found in all eight (100%), in 11 out o f  13 
(84.6%), in 6 out o f 11 (54.5%) and in none out of two (0%) spec­
imens o f  well, moderately, poorly differentiated squamous cell 
carcinoma and undifferentiated carcinoma respectively. There was 
an obvious relationship between the expression of SKALP/elafin  
and the differentiation o f  squamous cell carcinoma o f the oesoph­
agus. The incidence o f  the expression tended to be increased in 
relation to the degree o f  the differentiation o f the tumour. Even in 
moderately or poorly differentiated squamous cell carcinoma, the 
expression was observed only in cancer cells of tumour cell nests 
showing a clear squamous phenotype (Figure 4). Undifferentiated 
carcinoma cells did not express SKALP/elafin at all.
In this study, there was no relationship between the expression 
o f  SKALP/elafin and other clinicopathological factors, such as 
depth o f  invasion, lymph node mctastascs and histological stage.
In oesophageal cancer, PCNA was found to be expressed in all 
specimens with variations in the number o f positive cells anti 
staining intensity. In tumour cell nests, PCNA was found to be
in the cells of the basal layer. The existence of
SKALP/elafin immunoreactivity in cancer cells overlying the
PCNA-expressing cell layer was in serial sections
(Figure 3B). As seen in non-malignant hyperplastic oesophageal 
mucosa, both cell layers were clearly separated, and no expression 
was found in the cells that expressed PCNA.
D N A  fragmentation detected by the TUNEL method was also 
found in all specimens with variations in the number o f  positive 
cells and staining intensity. Characteristically, in tumour cell nests, 
D N A  fragmentation was found in the cells underneath the com i­
lled cell layer (Figure 3C). These cells were found to be similar to 
the SKALP/elafin-expressing cells in serial sections.
DISCUSSION
We have demonstrated that SKALP/elafin immunoreactivity was 
expressed in the mucosal area with submucosal inflammatory cell
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infiltration or with mucosal damage in non-malignant oesophageal 
mucosa. The expression o f SKALP/elafin was localized in the 
cells adjacent to PCNA-expressing basal cells. The expression was 
not observed in the cells o f  normal oesophageal mucosa nor in the 
basal cells. These immunohistochemical findings observed in 
this study correlate with previous findings oil the presence o f  
SKALP/elafin immunoreactivity in normal and psoriatic skin. It 
was found in the skin under inflammatory conditions but not in 
normal skin (Schalkwijk et al, 1993), indicating that SKALP/elafin 
could be induced in normal human skin under inflammatory condi­
tions or in the process o f  wound healing (Schalkwijk et al, 1991;
Alkemade et al, 1993).
It has been proved that SKALP/elafin inhibits the activities o f  at 
least three serine proteinases derived from polymorphonuclear 
leucocytes (PMN), such as human leucocyte elastase, porcine 
pancreatic elastase and human leucocyte proteinase 3 (Schalkwijk 
et al, 1990, 1991; Wiedow et al, 1991), The secretion of SKALP/ 
elafin from cultured human keratinocytes has 
(Molhuizen et al, 1993). Therefore, the present findings suggest 
that SKALP/elafin could be produced and secreted from the squa­
mous cells o f  the oesophagus to protect the mucosa from PMN 
serine proteinases under inflammatory conditions. Under these 
circumstances, SKALP/elafin could act as a negative feedback on
and the cloning o f its cDNA has revealed that the existence o f a 
mature protein, which upon cleavage o f  a hydrophobic signal 
sequence o f  22 amino acids has a calculated molecular mass o f  
9.9 kDa (95 amino acids) (Molhuizen et al, 1993). The mature 
protein contains a domain with four repeats which are homologous 
to putative transglutaminase substrate motifs. It has been found 
that both the complete SKALP molecule and a synthetic peptide of 
the NH2-tenninaI portion o f SKALP could be used as a transglut­
aminase substrate and is involved in the cornified envelope forma­
tion (Molhuizen et al, 1993). Therefore, the staining o f  the cell 
wall o f  the cornified cells in tumour cell nests suggests that 
SKALP/elafin is involved in the cornified envelope formation in
the ammatory response.
tumour cell nests o f  oesophageal cancer. This finding also supports 
the relationship between the expression of SKALP/elafin and the 
cell differentiation of squamous cell carcinoma of the oesophagus.
As seen in non-malignant oesophageal mucosa, the expression 
o f  SKALP/elafin was limited in the cells overlying PCNA- 
expressing cells in tumour cell nests, and the expression was not 
found in cells that expressed PCNA. In tumour cell nests, DNA  
fragmentation was often observed in the same cell layers as those 
in which SKALP/elafin was found. From these observations, it is 
considered that SKALP/elafin may induce the cell differentiation 
and further apoptosis of squamous cell carcinoma 
Furthermore, as no expression of this enzyme inhibitor was found
In the mucosal area showing hyperplastic changes, PCNA was in poorly differentiated or undifferentiated cancer cells, lack of  
found in the nucleus o f hyperplastic basal cells; but no expression production o f this enzyme inhibitor may be involved in the malig- 
of SKALP/elafin was observed in basal cells. The expression o f  nancy o f human squamous cell carcinoma o f the oesophagus.
SKALP/elafin was limited in the cells o f  the stratified zone adja­
cent to PCNA-expressing basal cells. Thus it could be considered 
to be involved in the regenerative/hyperproliferative differentia-
Several protease inhibitors, such as TIMPs (tissue inhibitor of 
metalloproteases), PAI-1 and PA 1-2 (plasminogen activator 
inhibitor type 1 and type 2), and urinary trypsin inhibitor have
tion programme (Alkemade et al, 1993) rather than the normal been reported lo possess the ability to inhibit cell growth and cell
differentiation o f  human oesophageal mucosa.
In oesophageal cancer, the incidence o f  the expression was
invasion of carcinoma cells in vitro (Baker et al, 1990; Cajot et al,
1 ; Albini et al, 1991; Declerck et al, 1992; Kennedy
significantly related to the degree of the differentiation of the Kobayashi et al, 1994, 1995). Recently, transfection o f maspin,
tumour. The strong expression of SKALP/elafin was observed in which is a newly purified serine pro tease inhibitor, has been
tumour cell nests that had a clear squamous phenotype-accompa- reported to reduce the malignancy of breast cancer cells (Zou et al,
nied by clear keratinization. In moderately or poorly differentiated 1994). The present results together with previous findings suggest
squamous cell carcinoma, the expression was localized in tumour that SKALP/elafin may possess the potential to reduce the malig- 
cell nests and the expression was not found in poorly differentiated nancy o f human squamous cell carcinoma o f  the oesophagus and 
or undifferentiated cells within these cancers. The present findings could be a unique tool for the development of a new therapeutic
suggest that the expression o f  SKALP/elafin is closely related to 
the differentiation o f  squamous cell carcinoma o f  the human 
oesophagus.
In this study, cytoplasmic staining was observed in the cancer 
cells overlying PCNA-expressing cells in tumour cell nests. On the 
other hand, the wall o f  the cornified cells in tumour cell nests was 
often found to be stained. Previous studies have shown (hat 
SKALP/elafin exists in multiple forms (Sehalwijk et al, 1991; 
Alkemade et al, 1993; Molhuizen el al, 1993). The different forms 
of SKALP/elafin have been reported to be generated by various 
N-terminal deletions in squamous cell carcinoma and keraloaean- 
thoma of the skin (Alkemade el al, 1993). The antisera used in this 
study has been revealed to recognize all o f  these forms o f  
SKALP/elafin because the antisera was raised against a 
SKALP/elafin fragment containing anti-proteinase activity and 
which is located in the C-lerminal half o f  the mature 
SKALP/elafin molecule (Alkemade et al, 1993). Originally, 
SKALP/elafin has been reported lo be a proteinase inhibitor found 
in psoriatic epidermis as a short polypeptide o f  6 kDa (Sclu  
el al, 1991; Molhuizen et al, 1993). Further purification and 
terminal sequencing of SKALP/elafin from cultured kerati
method against this lethal neoplasm.
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